SpringWorks is a brand that is dedicated to unlocking the full potential of targeted oncology. They tirelessly pursue every possibility to create new breakthroughs in cancer treatment, fueled by a team of individuals who think hard, care hard, and act with urgency. Their mission is to provide answers to patients who can't afford to wait.

SpringWorks focuses on rare oncology, with late-stage programs aimed at developing best-in-class treatments for devastating diseases like desmoid tumors and neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN). They also work on BCMA combinations in multiple myeloma, using their gamma secretase inhibitor, nirogacestat, to enhance the effectiveness of BCMA-targeted therapies. Additionally, they undertake precision oncology studies to address biomarker-defined metastatic solid tumors.

The brand's core values drive their actions. They care deeply about patients, approach their work with ambition without ego, think deeply and act quickly, never settle for good enough, and work as a united team. SpringWorks is committed to pursuing new possibilities in targeted oncology to improve the outlook for people with cancer